###### Strengths and limitations of this study

-   All patients were planned for primary percutaneous coronary intervention (PPCI).

-   Current PPCI techniques and novel antiplatelet therapy were used.

-   Appropriate statistical methods used to adjust for baseline differences between genders.

-   Our analysis, although prespecified, is applicable to the population studied.

-   The large imbalance in the proportion of men and women included caused a reduced study power for definitely excluding significant differences in outcomes.

Introduction {#s1}
============

Recent studies have provided evidence of gender differences in the pathophysiology and the clinical expression of atherosclerosis.[@R1] Several registries in patients with ST-segment elevation myocardial infarction (STEMI) have consistently shown a considerably higher risk of adverse outcomes in women compared with men. Nevertheless, there are conflicting results regarding whether gender is an independent contributor to this observation or the higher risk in women depends on differences in baseline characteristics and comorbidities between genders.[@R2] Although registries of patients with STEMI usually include large, unselected populations, they share some inherent limitations. Their results are certainly influenced by differences between genders in the use of timely reperfusion therapy and evidence-based drug therapies as well as undetected confounding factors.[@R9] Therefore, reports of gender-based analyses of randomised controlled trials are of crucial importance in an effort to minimise inequality in the management and evaluate gender as a potential independent risk factor for adverse outcome. Only a few randomised trials of patients with STEMI treated with primary percutaneous coronary intervention (PPCI) have reported results in the context of gender.[@R11] New treatments (eg, ticagrelor or prasugrel), special efforts to reduce bleeding (ie, increased use of radial arterial access, provisional rather than routine use of glycoprotein (GP) IIb/IIIa inhibitor), shorter delay times to reperfusion and a growing awareness regarding gender differences in the management and importance of adherences to evidence-based treatment could contribute to improved ischaemic and bleeding outcomes in female patients with STEMI.

In the Administration of Ticagrelor in the catheterisation laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial, prehospital administration of ticagrelor appeared to be safe but did not significantly improve outcome compared with in-hospital administration in patients with STEMI, treated with PPCI according to the current modern standards.[@R13]

We present a prespecified gender analysis of the ATLANTIC trial, with the aim of studying the association between gender and outcome.

Methods {#s2}
=======

The ATLANTIC study was an international, randomised, double-blind, placebo-controlled study with 30 days follow-up. The design of the study, inclusion and exclusion criteria, outcome definitions and principal results have previously been described.[@R13] Briefly, 1862 patients presenting with STEMI, \<6 hours after symptom onset, were included and randomised to prehospital (in the ambulance) versus in-hospital (in the catheterisation laboratory) treatment with a loading dose of ticagrelor (180 mg) in addition to aspirin and standard clinical care. All patients were to subsequently receive ticagrelor 90 mg twice daily for 30 days, after which it was recommended that ticagrelor should be continued for up to 12 months. Prehospital administration of a GP IIb/IIIa inhibitor was left to the physician's discretion. Periprocedural use of parenteral anticoagulants was also left to the physician's discretion, according to the local practice.

The proportion of patients who did not have ≥70% resolution of ST-segment elevation before PCI and/or did not meet the criteria for Thrombolysis In Myocardial Infarction (TIMI) flow 3 in the infarct-related artery (IRA) at initial angiography was the primary outcome of the ATLANTIC trial. Secondary outcomes (clinical efficacy outcomes) included the composite of death, MI, stent thrombosis, stroke or urgent revascularisation at 30 days and definite stent thrombosis at 30 days. Safety outcomes included major and minor bleeding over the 30-day treatment period. Bleeding risk was evaluated using the TIMI, Bleeding Academic Research Consortium (BARC) and Study of Platelet Inhibition and Patient Outcomes (PLATO) bleeding definitions.[@R14]

The main objective of our analysis was to study the association between gender and primary and secondary outcomes of the main study with a special focus on the clinical efficacy and safety outcomes. The interaction of gender subgroups with randomised treatment effects was also investigated.

The trial design and protocol were approved by the national regulatory authorities in all the participating countries and by the local ethics committee or institutional review board at each participating site. All patients provided written informed consent.

Statistical analysis {#s3}
====================

Continuous variables are presented by their mean and SD or median and 25th−75th percentiles as appropriate. Categorical variables are presented as counts and percentages. Baseline and periprocedural characteristics were compared according to gender by χ^2^ tests for categorical variables and Student's t-test or Mann-Whitney U test for continuous variables, depending on if the variable of interest was normally distributed or not. A p value \<0.05 is considered to indicate statistical significance.

The incidence of events over time by gender is presented by Kaplan-Meier curves.

In order to study the association between gender and the clinical efficacy and safety outcomes, independent of randomised treatment as well as the possible interactions between gender and randomised treatment with respect to the outcomes, HRs with 95% CIs were derived from Cox proportional hazards models. In the unadjusted (crude) model, gender was the only explanatory variable whereas in the adjusted multivariable model, gender was forcibly included and the other variables were chosen by using a forward stepwise selection algorithm with a significant cut-off level of 0.05 for inclusion. Selection of covariates included in the multivariable analysis was based on previous studies[@R3] and clinical experience. Univariate analysis was not performed. However, this is a common practice in observational studies and we included 18 covariates in our multivariable analysis that, we believe, incorporated all possible predictors of adverse outcomes in a STEMI population.

Adjustment variables included age, weight, prior MI, prior PCI, patient's history of diabetes, hypertension, non-haemorrhagic stroke, gastrointestinal bleeding, time from symptom onset to pre-PCI ECG, admission Killip class (as a dichotomous variable 1/\>1), baseline haemoglobin, estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) formula, access site, use of GP IIIb/IIa inhibitor, bivalirudin and unfractionated heparin (UFH), location of MI and revascularisation. To evaluate the importance of early mortality, a landmark analysis of the clinical efficacy outcomes was also performed from 48 hours after randomisation (arbitrarily defined) to the end of the study. In order to explore the importance of bleeding on the clinical efficacy outcomes, a separate analysis was also performed by censoring the patients who reported a PLATO major bleeding at the time of the onset of a bleeding event.

A comparable statistical process was used to compare gender differences in the effect of randomised treatment by constructing logistic regression models. ORs with 95% CIs were presented. The above process for Cox regression and logistic regression was also used to explore the interaction effect of gender and treatment.

For most of the variables included in the multivariable models, only few patients had missing data (\<10 patients). However, 7% of patients had missing values for creatinine, 5% for haemoglobin and 4% for Killip class. The number of patients with complete data for multivariable Cox proportional hazard models of the primary outcome was 1613 (88%).

All the analyses were performed using SAS v.9.3.

Results {#s4}
=======

Baseline and periprocedural characteristics stratified by gender {#s4a}
----------------------------------------------------------------

### Demographic and clinical characteristics {#s4a1}

The study population consisted of 369 (20%) women. They were older (mean age 69 vs 59 years, p\<0.01), had lower body mass index (BMI), higher TIMI risk score, more often had a history of hypertension, chronic obstructive pulmonary disease and stroke. Men had more frequent prior PCI. No difference was observed between genders with respect to acute heart failure (Killip class \>1) and only a minority of patients presented with cardiogenic shock ([table 1](#T1){ref-type="table"}).

###### 

Baseline, clinical and periprocedural characteristics according to gender

  Characteristics                                                           Women (n=369)       Men (n=1493)        p Value
  ------------------------------------------------------------------------- ------------------- ------------------- ---------
  Age, years; mean (SD)                                                     69 (13.0)           59 (11)             \<0.01
  Age ≥75 years                                                             153 (41.5)          151 (10.1)          \<0.01
  BMI, kg/m^2^; median (IQR)                                                25.6 (22.5--29.1)   26.5 (24.3--29.4)   \<0.01
  Patient's history of:                                                                                             
   Diabetes mellitus                                                        48 (13.0)           205 (13.7)          0.72
   Hypertension                                                             190 (51.5)          605 (40.5)          \<0.01
   Dyslipidemia                                                             117 (31.7)          536 (35.9)          0.13
   Angina                                                                   36 (9.8)            157 (10.5)          0.67
   Prior myocardial infarction                                              24 (6.5)            135 (9.0)           0.67
   Prior PCI                                                                16 (4.3)            124 (8.3)           \<0.01
   Prior CABG                                                               1 (0.3)             11 (0.7)            0.32
   Prior non-haemorrhagic stroke                                            8 (2.2)             10 (0.7)            \<0.01
   Chronic obstructive pulmonary disease                                    22 (6.0)            54 (3.6)            0.04
   Gastrointestinal bleeding                                                1 (0.3)             16 (1.1)            0.15
   Chronic renal disease                                                    7 (1.9)             27 (1.8)            0.91
  Index event information                                                                                           
   First medical contact in ambulance                                       280 (75.9)          1132 (75.8)         0.24
   Minutes from symptom onset to prehospital ECG, median (IQR)              88 (49--169)        70 (41--129)        \<0.01
   Minutes from prehospital ECG to PCI, median (IQR)                        83 (68--101)        80 (66--96)         0.03
   Minutes from pre-PCI angiography to post-PCI angiography, median (IQR)   36 (24--52)         32 (23--45)         0.03
   Received first loading dose                                              369 (100)           1488 (99.7)         0.27
  Risk level at admission                                                                                           
   Killip class                                                                                                     
    I                                                                       332 (90.0)          1349 (90.4)         0.82
    IV                                                                      2 (0,5)             3 (0.2)             
   TIMI risk score                                                                                                  
    0--2                                                                    119 (32.2)          1006 (67.4)         0.01
    3--6                                                                    231 (62.6)          471 (31.5)          
    \>6                                                                     19 (5.1)            16 (1.1)            
   Culprit vessel                                                                                                   
   Left main artery                                                         4 (1.1)             18 (1.2)            0.63
   Left anterior descending artery                                          141 (38.8)          571 (39.0)          
   Right coronary artery                                                    150 (41.3)          590 (40.3)          
   Left circumflex                                                          39 (10.7)           196 (13.4)          
   No culprit vessel identified                                             28 (7.7)            85 (5.8)            
   Normal coronary angiography                                              27 (7.4)            76 (5.2)            0.1
  Procedures for index event                                                                                        
   Femoral access                                                           144 (39.7)          445 (30.4)          \<0.01
   Thromboaspiration                                                        160 (43.4)          781 (52.3)          \<0.01
   PCI                                                                      309 (83.7)          1321 (88.5)         0.01
    With any stent                                                          288 (78.0)          1248 (83.6)         0.01
    With DES                                                                185 (50.1)          761 (51.0)          0.77
   Coronary artery bypass grafting                                          4 (1.1)             21 (1.4)            0.63
   No revascularisation                                                     56 (15.2)           151 (10.1)          \<0.01
  Any glycoprotein IIb/IIIa inhibitor use                                   115 (31.2)          598 (40.1)          \<0.01
  Glycoprotein IIb/IIIa inhibitor use before angiography                    14 (3.8)            116 (7.8)           \<0.01
  Intravenous anticoagulant prior to pre-PCI angiography                    231 (62.6)          1027 (68.8)         0.02
  Intravenous anticoagulant during hospitalisation\*                        310 (84.0)          1332 (89.2)         \<0.01
   Heparin only                                                             135 (36.6)          584 (39.1)          0.02
   Bivalirudin only                                                         29 (7.9)            65 (4.4)            0.02

Variables presented as numbers (percentages) unless otherwise indicated.

\*Includes all intravenous medications given on the date of the qualifying ECG and/or index PCI.

BMI, body mass index; CABG, coronary artery bypass grafting; DES, drug-eluting stent; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction.

### Time delays {#s4a2}

Women had significantly longer delay times, both from symptom onset to prehospital ECG (median 88 vs 70 min, p\<0.01) and from pre-PCI to post-PCI angiography (median 36 vs 32 min, p=0.03).

### Procedural characteristics, angiographic findings and medication during the index event {#s4a3}

Coronary angiography was more often performed by femoral access in women (39.7% vs 30.4%, p\<0.01). The genders did not differ according to IRA, with the left anterior descending artery involved in 38% of women and 39% of men. PPCI, with or without stent, was performed significantly more often in men (88.5% vs 83.7%, p\<0.01), whereas the use of drug-eluting stents was similar. Thromboaspiration, GP IIb/IIIa inhibitors and intravenous anticoagulants were used less often in women ([table 1](#T1){ref-type="table"}).

Association between gender and outcomes independent of randomised treatment {#s4b}
---------------------------------------------------------------------------

Female gender was associated with significantly higher risk for the composite outcome of death, MI, stroke, urgent revascularisation or definite acute stent thrombosis compared with male gender (6.8% vs 3.9%, crude HR 1.79, 95% CI 1.12 to 2.86) ([figure 1](#F1){ref-type="fig"}). This difference was mainly driven by a threefold higher risk for all-cause mortality in women compared with men (5.7% vs 1.9%, HR 3.13, 95% CI 1.78 to 5.51). Although the difference was attenuated in the multivariable model, gender was still associated with all-cause mortality at 30 days (HR 2.08, 95% CI 1.03 to 4.20) ([figure 2](#F2){ref-type="fig"} and [table 2](#T2){ref-type="table"}). Landmark analysis for events occurring within 48 hours, and between 48 hours and 30 days showed that 38% of the women and 36% of the men who did not survive the first month died within 48 hours. Comparison after excluding patients from further analysis at the time point of a PLATO major bleeding event still revealed a statistically significant association between women and all-cause mortality (4.3% vs 1.4%. HR 3.20, 95% CI 1.67 to 6.13). Similar result was obtained after adjustment but the difference between genders did not reach statistical significance (HR 2.15, 95% CI 0.93 to 5.00).

![Cumulative Kaplan-Meier (KM) estimates of the incidence of the composite endpoint (EP) of death, MI, stroke, urgent revascularisation or definite acute stent thrombosis and all-cause mortality at 30 days by gender.](bmjopen-2016-015241f01){#F1}

![Association between gender and clinical efficacy and safety outcomes independent of randomised treatment.](bmjopen-2016-015241f02){#F2}

###### 

Association between gender and clinical outcomes independent of randomised treatment

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes                                                                                 Female (n=369)   Male (n=1489)   Crude HR (95% CI)\    Adjusted HR (95% CI)\*\   p Value \*
                                                                                                                            (n included=1858)     (n included=1613)         
  ---------------------------------------------------------------------------------------- ---------------- --------------- --------------------- ------------------------- ------------
  Mortality and cardiovascular outcomes                                                                                                                                     

   Composite of death/MI/stroke/urgent revascularisation/definite acute stent thrombosis   25 (6.8)         58 (3.9)        1.79 (1.12to 2.86)    1.32 (0.77to 2.27)        0.32

   Composite of death/MI/urgent revascularisation                                          23 (6.2)         50 (3.4)        1.91 (1.17 to 3.13)   1.33 (0.75to 2.36)        0.32

   All-cause mortality                                                                     21 (5.7)         28 (1.9)        3.13 (1.78 to 5.51)   2.08 (1.03to 4.20)        0.04

   Myocardial infarction                                                                   3 (0.8)          14 (0.9)        0.90 (0.26to 3.13)    0.82 (0.23to 2.85)        0.76

   Stroke                                                                                  3 (0.8)          3 (0.2)         4.18 (0.84to 20.70)   4.14 (0.84to 20.51)       0.08

   Urgent revascularisation                                                                2 (0.5)          11 (0.7)        0.75 (0.17to 3.38)    0.69 (0.15to 3.11)        0.63

   Definite acute stent thrombosis                                                         3 (0.8)          10 (0.7)        1.23 (0.34to 4.49)    1.29 (0.35to 4.76)        0.70

   Acute stent thrombosis (definite or probable)                                           11 (3.0)         30 (2.0)        1.53 (0.77to 3.05)    0.88 (0.39to 1.98)        0.76

  Safety outcomes                                                                                                                                                           

   PLATO major bleeding†                                                                   17 (4.6)         33 (2.2)        2.15 (1.20to 3.85)    1.45 (0.73to 2.86)        0.29

   TIMI major bleeding†                                                                    10 (2.7)         14 (0.9)        2.95 (1.31to 6-65)    1.28 (0.47to 3.48)        0.63

   TIMI major or minor bleeding†                                                           18 (4.9)         54 (3.6)        1.38 (0.81to 2.35)    0.94 (0.51to 1.74)        0.85

   BARC type 3--5 (major) bleeding†                                                        16 (4.3)         31 (2.1)        2.15 (1.18to 3.93)    1.45 (0.72to 2.91)        0.30

   BARC type 2--5 (major or minor) bleeding†                                               20 (5.4)         56 (3.8)        1.48 (0.89to 2.47)    1.03 (0.57to 1.84)        0.93
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*HR (for female vs male) and p value calculated from logistic regression model including gender, age, weight, prior myocardial infarction, prior percutaneous coronary intervention, diabetes, hypertension, non-haemorrhagic stroke, gastrointestinal bleeding, time from symptom onset to prehospital ECG, admission Killip class, baseline haemoglobin, estimated glomerular filtration rate, access site, glycoprotein IIb/IIIa inhibitor, bivalirudin or unfractionated heparin use during index procedure, revascularisation and location of myocardial infarction

†Non-CABG-related bleeding occurring up to the date of the last study visit (to the maximum of 32 days) are included in the table.

BARC, Bleeding Academic Research Consortium; CABG, coronary artery bypass grafting; MI, myocardial infarction; PLATO, Study of Platelet Inhibition and Patient Outcomes; TIMI, Thrombolysis in Myocardial Infarction.

Female gender was associated with lower risk for TIMI flow \<3 in the IRA at initial angiography (adjusted OR 0.67, 95% CI 0.47 to 0.96). The risk of incomplete ST-segment elevation resolution (\<70%) before PCI did not differ significantly between the genders (adjusted OR 1.11, 95% CI 0.73 to 1.71). The risk of abnormal TIMI flow in the IRA and incomplete ST-segment elevation resolution after PCI was similar in both genders ([figure 3](#F3){ref-type="fig"}).

![Association between gender and primary and secondary outcomes, independent of randomised treatment.](bmjopen-2016-015241f03){#F3}

Women had significantly higher risk for major bleeding complications compared with men, irrespective of the bleeding definition used (30-day PLATO major bleeding 4.6% vs 2.2%, HR 2.15, 95% CI 1.18 to 3.85, TIMI major bleeding at 30 days 2.7% vs 0.9%, HR 2.95, 95% CI 1.31 to 6.65, BARC type 3--5 bleeding 4.3% vs 2.1%, HR 2.15, 95% CI 1.18 to 3.93) ([figure 4](#F4){ref-type="fig"}). However, after adjustment for baseline and clinical characteristics, female gender was no longer an independent predictor of risk for bleeding at 30 days ([table 2](#T2){ref-type="table"} and [figure 2](#F2){ref-type="fig"}).

![Cumulative Kaplan-Meier (KM) estimates of the incidence of the Thrombolysis In Myocardial Infarction (TIMI) major bleeding and Bleeding Academic Research Consortium (BARC) type 3--5 bleeding at 30 days by gender.](bmjopen-2016-015241f04){#F4}

Association between gender and efficacy and safety of randomised treatment {#s4c}
--------------------------------------------------------------------------

Prehospital administration of ticagrelor compared with in-hospital administration resulted in a non-significant difference in the primary, secondary and safety outcomes. No significant interactions between randomised treatment and gender in terms of these outcomes were found in the unadjusted or adjusted model (test for interaction in the multivariable models; p=0.94 for all-cause mortality, p=0.55 for absence of TIMI flow grade 3 in the IRA at initial angiography, p=0.71 for absence of ≥70% resolution of pre-PCI ST-segment elevation, and p=0.31 for TIMI major bleeding at 30 days) (see online [supplementary tables 1--3](#SP1){ref-type="supplementary-material"}).
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Discussion {#s5}
==========

In the present analysis, unadjusted data showed a significantly higher risk of short-term mortality and bleeding complications in women. After multivariable adjustment female gender remained an independent predictor of mortality, whereas advanced age and comorbidities could mainly explain the higher incidence of bleeding complications in women.

Undoubtedly, older age and clustering of comorbidities in women could explain a large part of the observed difference in short-term clinical outcomes in our study. However, the adjusted risk for death was still significantly higher in women. The contribution of gender, as independent risk factor, on adverse outcome may depend on the population studied. The age gap between genders in our population was substantially higher compared with previous studies, with a mean age difference of 10 years.[@R12] In spite of appropriate statistical methods that were used for adjustment, adjustment for such age difference is awkward. Additionally, the age difference may indicate a selection bias. As identification and randomisation took place in the ambulance, young women with suspected STEMI were possibly not included in the study as alternative reasons for ST-segment elevation on prehospital ECG may have been considered more plausible in this group. Furthermore, a trend towards increased mortality with prehospital ticagrelor was observed in the ATLANTIC trial that was mainly attributed to a plausible imbalance between the two groups in terms of the severity of the presenting event. Given the low rate of all-cause mortality, unobserved confounders in elderly women with STEMI may have significantly contributed to our results and the findings of the main study. These factors may have a significant impact on the remaining higher adjusted risk for short-term mortality in women.

Previous observational studies in STEMI cohorts, without focus on patients treated with PPCI have shown a higher risk for early mortality in women.[@R6] Significant differences in the rate of reperfusion therapy between genders and hidden confounders such as frailty in elderly women with STEMI may have influenced their results. Recent observational studies including patients treated with PPCI[@R4] and prespecified gender analysis of randomised controlled trials[@R11] have shown that the impact of gender on mortality could mainly be explained by differences in age and comorbidities between genders. On the contrary, an observational study and a meta-analysis have reported higher multivariable adjusted risk of early mortality in women with STEMI treated with PPCI.[@R23] Differences in the population studied and in the covariates included in the multivariable analysis between studies may explain the conflicting results. Previous studies have clearly demonstrated the importance of body surface area and the eGFR on prognosis.[@R25] In a meta-analysis, Berger *et al* showed that female gender was an independent predictor of early mortality in patients with STEMI. However, 30-day mortality was not statistically significant different between genders after additional adjustment for angiographic disease severity.[@R27]

In the present study, women had two to three times higher unadjusted risk for non-CABG-related bleedings, depending on the definition used. After adjustment for baseline characteristics, no significant difference remained. Female gender has previously been associated with higher risk for bleeding complications in patients with acute coronary syndrome.[@R28] Known predictors of bleedings like advanced age, diabetes, hypertension, renal insufficiency and anaemia, are usually more often encountered in women with STEMI.[@R15] Additionally, smaller body and vessel size, higher use of femoral access and overdosing of antithrombotic medication in women may explain the higher observed risk for bleeding. Procedural-related improvement such as increased use of radial access or smaller femoral sheaths and careful dose adjustment of antithrombotic medication, have resulted in a significant decline in the risk of bleeding/vascular complication during cardiovascular interventions the last years and have probably contributed to our results.[@R32] The negative impact of bleedings on prognosis in patients with STEMI is well established.[@R15] Our data showed that even after excluding patients from further analysis at the time of a PLATO major bleeding, the HR for early mortality in women versus men remained unchanged, implying that reducing the rate of major bleeding in women may improve their prognosis but is not the main reason for the observed difference between genders in the early mortality.

Some well-known gender disparities in the concomitant management of patients with STEMI remained unchanged. Women were less likely to be treated with GP IIb/IIIa inhibitors and thromboaspiration during PPCI despite lack of gender difference in protection from major adverse outcomes by GP IIb/IIIa inhibitors[@R33] and benefit of thromboaspiration at the time when the study was conducted.[@R34] Similar findings have been provided by large registries.[@R7] Some of these lower rates of utilisation may be 'appropriate' given the higher TIMI 3 flow rates in the IRA pre-PPCI and lower rates of PPCI in women versus men. Furthermore, physician's concern for higher risk of bleeding in older women with STEMI have certainly contributed to the lower use of GP IIb/IIIa inhibitors in women.

Although the impact of early reperfusion on mortality in patients with STEMI is now unquestionable,[@R35] patients' delay from symptom onset to prehospital ECG was not an independent predictor of mortality in our study, in agreement with results from previous gender analyses.[@R36] A plausible explanation is an association between age and delay, and thus adjustment for age minimises the relative impact of delay. Furthermore, in PPCI, female gender has been associated with similar or even smaller infarct size than that in male gender, despite longer prehospital delays, indicating that other factors than larger infarct size secondary to longer prehospital delay mainly contribute to the observed higher unadjusted short-term mortality.[@R36] The proportion of 30-day mortality that occurred within 48 hours of admission was similar in women and men (38% vs 36%, respectively) contrasting previous data where gender differences in early mortality were accounted for by excess very early (within 24--48 hours) deaths in women with STEMI.[@R7] Cardiogenic shock and haemodynamic instability were key exclusion criteria in the ATLANTIC trial, which may have influenced these results. Cardiogenic shock has been shown to be more common in women and female gender has been highly associated with mortality in shock patients.[@R20]

In terms of ST-segment elevation resolution and TIMI flow 3 rates before and after PCI, no significant difference between genders was observed apart from a lower risk of abnormal coronary flow in IRA at initial angiography in women. The higher rate of TIMI flow 3 at initial angiography may be explained by the higher rate of normal coronary arteries as well as the less obstructive coronary artery disease in women with STEMI, which is in concordance with previous data.[@R37]

The analysis of the effect of gender on outcomes dependent on the randomised treatment showed no statistically significant interactions. Prehospital administration of ticagrelor did not improve pre-PCI or post-PCI coronary reperfusion as assessed by TIMI flow in IRA and resolution of ST elevation pre-PCI. Clinical efficacy outcomes were not significantly improved either. However, prehospital administration of ticagrelor was safe in both genders with similar rate of major and minor bleedings.

Strengths and limitations {#s6}
=========================

The present study has some important limitations. Our results are applicable to the populations studied, patients with STEMI pretreated with ticagrelor and planned for primary PCI.

The ATLANTIC study population is from a randomised controlled trial, with inclusion and exclusion criteria contributing to differences relative to populations treated in routine clinical practice, and thereby limiting generalisability. However, the proportion of elderly patients (\>75 years) was higher than in the PLATO trial, especially for women, and under-representation of women in clinical trials is a well-recognised problem. Moreover, the study was conducted at several centres and countries increasing external validity. Taken together, our results should be applied to a real-world STEMI population with caution.

Additionally, the ATLANTIC trial was not stratified by gender. The large imbalance in the proportion of men and women included, commonly encountered in a STEMI population, caused a reduced power for detecting or definitely excluding significant differences in some outcomes between the genders or to definitely exclude an interaction between gender and the randomised treatment.

The most important strength of our analysis is that patients were treated according to the current guidelines of STEMI, with PPCI as the reperfusion strategy of choice, administration of the modern ADP receptor blocker ticagrelor in addition to aspirin as soon as possible after the first medical contact, high use of radial access during catheterisation and adjuvant pharmacological treatment during PPCI with UFH or bivalirudin.[@R38] Therefore, our study provides important information about differences and similarities between genders in patients with STEMI treated with current PCI techniques and pharmacological treatment.

Conclusion {#s7}
==========

In patients with STEMI, planned for PPCI and treated with modern antiplatelet therapy, female gender identifies a group of patients with high risk of early mortality in whom prompt efforts to improve outcome are warranted. Female gender was not an independent predictor of bleeding but advanced age and clustering of comorbidities in women could mainly explain their higher unadjusted risk for bleeding events compared with men. Prehospital administration of ticagrelor had a similar efficacy and safety profile in men and women with STEMI.
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